Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company, has a lead program entering Phase 3 for hypertriglyceridemia. The company’s cardiovascular programs take advantage of the staff’s expertise in the field of lipid science and the acknowledged therapeutic benefits of essential fatty acids in cardiovascular disease. In addition to Amarin’s lead program, their pipeline includes programs in myasthenia gravis, Huntington’s disease, Parkinson’s disease and epilepsy. For further information, visit the Company’s web site at www.amarincorp.com.
Archive for the ‘Amarin Corp. AMRN’ Category
Amarin Corporation (NASDAQ: AMRN) is a neuroscience company focused on the research, development and commercialization of novel drugs that address unmet patient needs. Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases.
Amarin continues to focus their efforts on employing a novel, proprietary platform based on knowledge of the chemical nature and highly vascular environment of the brain to develop pharmaceuticals in the area of neurology. The company’s unique technology of lipophilic drugs is predominately fat-soluble, which helps facilitate transportation across the blood-brain barrier. This is a crucial component since the majority of drugs that are currently available to treat neurological and psychiatric disorders have mechanisms of action targeting receptors of the brain or neurotransmitters located in the brain’s makeup.
The company has initiated a cardiovascular development program to capitalize on the known therapeutic benefits of unsaturated fatty acids in cardiovascular disease. Amarin plans to utilize their extensive know-how and vast experience in lipid science to develop a series of products targeting the vascular system, endothelial dysfunction and vascular re-modeling. Amarin intends on commencing a series of clinical trials with AMR 101 in cardiovascular disease. In addition, Amarin plans to begin an extensive investigation of new compounds from their already existing lipid science platform for the treatment of cardiovascular disease.
Their current neuroscience development pipeline is comprised of four key clinical development programs plus several pre-clinical opportunities. Clinical programs include AMR 101 for Huntington’s disease, EN 101 for Myasthenia gravis, an oral formulation of apomorphine for treating advanced Parkinson’s disease and patient’s who experience frequent “off” episodes. Additional treatments include a nasal formulation of lorazepam for treating emergency epilepsy seizures in the out-patient setting, and brain targeted delivery of levodopa for Parkinson’s disease which utilizes Amarin’s targeted transport lipid technology.
Let us hear your thoughts: Amarin Corp. Message Board